BACKGROUND: We sought to better define the role of hematopoietic cell transplantation (HCT) in first remission (CR1) for high-risk pediatric acute myeloid leukemia (AML). PROCEDURES: Outcomes were compared among patients aged less than 21 years with cytogenetically defined poor-risk AML treated with chemotherapy, matched related (MRD), or unrelated donor (URD) transplantation in CR1. Poor-risk cytogenetics was defined as monosomy 7/del7q, monosomy 5/del 5q, abnormalities of 3q, t(6;9)(p23;q34), or complex karyotype. Included are patients treated on Children's Oncology Group trials or reported to the Center for International Blood and Marrow Transplant Research from 1989 to 2006. RESULTS: Of the 233 patients, 123 received chemotherapy, 55 received MRD HCT, and 55 received URD HCT. The 5-year overall survival from the time of consolidation chemotherapy or transplant conditioning was similar: chemotherapy (43% ± 9%), MRD (46% ± 14%), or URD (50% ± 14%), P = 0.99. Similarly, multivariate analysis demonstrated no significant differences in survival [(reference group = chemotherapy); MRD HR 1.08, P = 0.76; URD HR 1.13, P = 0.67] despite lower relapse risk with URD HCT (HR = 0.43, P = 0.01). CONCLUSIONS: Our findings do not provide support for the preferential use of HCT over chemotherapy alone for children with cytogenetically defined poor-risk AML in CR1.
BACKGROUND: We sought to better define the role of hematopoietic cell transplantation (HCT) in first remission (CR1) for high-risk pediatric acute myeloid leukemia (AML). PROCEDURES: Outcomes were compared among patients aged less than 21 years with cytogenetically defined poor-risk AML treated with chemotherapy, matched related (MRD), or unrelated donor (URD) transplantation in CR1. Poor-risk cytogenetics was defined as monosomy 7/del7q, monosomy 5/del 5q, abnormalities of 3q, t(6;9)(p23;q34), or complex karyotype. Included are patients treated on Children's Oncology Group trials or reported to the Center for International Blood and Marrow Transplant Research from 1989 to 2006. RESULTS: Of the 233 patients, 123 received chemotherapy, 55 received MRD HCT, and 55 received URD HCT. The 5-year overall survival from the time of consolidation chemotherapy or transplant conditioning was similar: chemotherapy (43% ± 9%), MRD (46% ± 14%), or URD (50% ± 14%), P = 0.99. Similarly, multivariate analysis demonstrated no significant differences in survival [(reference group = chemotherapy); MRD HR 1.08, P = 0.76; URD HR 1.13, P = 0.67] despite lower relapse risk with URD HCT (HR = 0.43, P = 0.01). CONCLUSIONS: Our findings do not provide support for the preferential use of HCT over chemotherapy alone for children with cytogenetically defined poor-risk AML in CR1.
Authors: W G Woods; N Kobrinsky; J D Buckley; J W Lee; J Sanders; S Neudorf; S Gold; D R Barnard; J DeSwarte; K Dusenbery; D Kalousek; D C Arthur; B J Lange Journal: Blood Date: 1996-06-15 Impact factor: 22.113
Authors: Denise M Oliansky; J Douglas Rizzo; Peter D Aplan; Robert J Arceci; Louis Leone; Yaddanapudi Ravindranath; Jean E Sanders; Franklin O Smith; Fiona Wilmot; Philip L McCarthy; Theresa Hahn Journal: Biol Blood Marrow Transplant Date: 2007-01 Impact factor: 5.742
Authors: David Becton; Gary V Dahl; Yaddanapudi Ravindranath; Myron N Chang; Fred G Behm; Susana C Raimondi; David R Head; Kimo C Stine; Norman J Lacayo; Branimir Ivan Sikic; Robert J Arceci; Howard Weinstein Journal: Blood Date: 2005-10-27 Impact factor: 22.113
Authors: Ursula Creutzig; Marry M van den Heuvel-Eibrink; Brenda Gibson; Michael N Dworzak; Souichi Adachi; Eveline de Bont; Jochen Harbott; Henrik Hasle; Donna Johnston; Akitoshi Kinoshita; Thomas Lehrnbecher; Guy Leverger; Ester Mejstrikova; Soheil Meshinchi; Andrea Pession; Susana C Raimondi; Lillian Sung; Jan Stary; Christian M Zwaan; Gertjan J L Kaspers; Dirk Reinhardt Journal: Blood Date: 2012-08-09 Impact factor: 22.113
Authors: Henrik Hasle; Todd A Alonzo; Anne Auvrignon; Catherine Behar; Myron Chang; Ursula Creutzig; Alexandra Fischer; Erik Forestier; Alcira Fynn; Oskar A Haas; Jochen Harbott; Christine J Harrison; Nyla A Heerema; Marry M van den Heuvel-Eibrink; Gertjan J L Kaspers; Franco Locatelli; Peter Noellke; Sophia Polychronopoulou; Yaddanapudi Ravindranath; Bassem Razzouk; Dirk Reinhardt; Natalia N Savva; Batia Stark; Stefan Suciu; Ichiro Tsukimoto; David K Webb; Dorora Wojcik; William G Woods; Martin Zimmermann; Charlotte M Niemeyer; Susana C Raimondi Journal: Blood Date: 2007-02-13 Impact factor: 22.113
Authors: Beverly J Lange; Franklin O Smith; James Feusner; Dorothy R Barnard; Patricia Dinndorf; Stephen Feig; Nyla A Heerema; Carola Arndt; Robert J Arceci; Nita Seibel; Margie Weiman; Kathryn Dusenbery; Kevin Shannon; Sandra Luna-Fineman; Robert B Gerbing; Todd A Alonzo Journal: Blood Date: 2007-11-13 Impact factor: 22.113
Authors: D Grimwade; H Walker; F Oliver; K Wheatley; C Harrison; G Harrison; J Rees; I Hann; R Stevens; A Burnett; A Goldstone Journal: Blood Date: 1998-10-01 Impact factor: 22.113
Authors: Martin G Sauer; Peter J Lang; Michael H Albert; Peter Bader; Ursula Creutzig; Matthias Eyrich; Johann Greil; Bernd Gruhn; Wolfgang Holter; Thomas Klingebiel; Bernhard Kremens; Heiko von der Leyen; Christine Mauz-Körholz; Roland Meisel; Kirsten Mischke; Ingo Müller; Charlotte M Niemeyer; Christina Peters; Christine Pohler; Dirk Reinhardt; Birgit Burkhardt; Paul G Schlegel; Ansgar S Schulz; Johanna Schrum; Petr Sedlacek; Brigitte Strahm; Wilhelm Woessmann; Rupert Handgretinger; Martin Zimmermann; Arndt Borkhardt Journal: Leukemia Date: 2019-10-02 Impact factor: 11.528
Authors: F Locatelli; R Masetti; R Rondelli; M Zecca; F Fagioli; A Rovelli; C Messina; E Lanino; A Bertaina; C Favre; G Giorgiani; M Ripaldi; O Ziino; G Palumbo; M Pillon; A Pession; S Rutella; A Prete Journal: Bone Marrow Transplant Date: 2014-11-10 Impact factor: 5.483
Authors: Thomas B Alexander; Lei Wang; Hiroto Inaba; Brandon M Triplett; Stanley Pounds; Raul C Ribeiro; Ching-Hon Pui; Jeffrey E Rubnitz Journal: Cancer Date: 2017-05-30 Impact factor: 6.860
Authors: Menachem Bitan; Wensheng He; Mei-Jie Zhang; Hisham Abdel-Azim; Mouhab Fakhreddine Ayas; Bella Bielorai; Paul A Carpenter; Mitchell S Cairo; Miguel Angel Diaz; John T Horan; Sonata Jodele; Carrie L Kitko; Kirk R Schultz; Morris Kletzel; Kimberly A Kasow; Leslie E Lehmann; Parinda A Mehta; Nirali Shah; Michael A Pulsipher; Tim Prestidge; Adriana Seber; Shalini Shenoy; Ann E Woolfrey; Lolie C Yu; Stella M Davies Journal: Blood Date: 2014-01-16 Impact factor: 22.113
Authors: A-L Alloin; G Leverger; J-H Dalle; C Galambrun; Y Bertrand; A Baruchel; A Auvrignon; V Gandemer; C Ragu; A Loundou; C Bilhou-Nabera; M Lafage-Pochitaloff; N Dastugue; B Nelken; C Jubert; F Rialland; G Plat; C Pochon; J-P Vannier; P-S Rohrlich; J Kanold; P Lutz; A Sirvent; C Oudin; W Cuccuini; G Michel Journal: Bone Marrow Transplant Date: 2016-12-12 Impact factor: 5.483